Summit Therapeutics SMMT Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's business segments — stock-based comp?
- Summit Therapeutics (SMMT) reported business segments — stock-based comp of $72.79M in Q1 2026.
- How has Summit Therapeutics's business segments — stock-based comp changed year-over-year?
- Summit Therapeutics's business segments — stock-based comp increased by 556.0% year-over-year, from $11.1M to $72.79M.
- What is the long-term trend for Summit Therapeutics's business segments — stock-based comp?
- Over 3 years (2022 to 2025), Summit Therapeutics's business segments — stock-based comp has grown at a 294.3% compound annual growth rate (CAGR), from $11.95M to $732.42M.
- What does business segments — stock-based comp mean?
- The accounting cost of employee stock awards and options allocated to this segment.
- How do you interpret business segments — stock-based comp?
- High levels indicate significant use of equity for talent retention, which dilutes shareholders but preserves cash; sudden spikes often reflect new grant cycles.
- How does business segments — stock-based comp compare across companies?
- Standard line item for technology and biotech firms; highly variable based on compensation strategy and stock price volatility.